PDF herunterladen
Handchir Mikrochir Plast Chir 2019; 51(04): 262-274
DOI: 10.1055/a-0627-7333
Consensus Statement
© Georg Thieme Verlag KG Stuttgart · New York

Therapie der Dupuytren’schen Kontraktur mit Kollagenase

Evidenz-basiertes Konsensus Statement[1] chirurgischer Fachgesellschaften ÖsterreichsTherapy of Dupuytren’s contracture with collagenaseEvidence-based Consensus Statement of Austrian Surgical Societies
Werner Girsch
1   LKH - Universitätsklinikum Graz/Klinische Abteilung für Plastische, Ästhetische & Rekonstruktive Chirurgie, Graz
,
Rohit Arora
2   Univ.-Klinik für Unfallchirurgie Innsbruck, Innsbruck
,
Eva-Maria Baur
3   Univ.-Klinik für Plastische, Rekonstruktive und Ästhetische Chirurgie Innsbruck, Innsbruck
,
Markus Gabl
2   Univ.-Klinik für Unfallchirurgie Innsbruck, Innsbruck
,
Dietmar Hager
4   niedergelassener Facharzt für Unfallchirurgie, Linz
,
Thomas Hintringer
5   Krankenhaus der Barmherzigen Schwestern/ Abteilung für Plastische, Ästhetische und Rekonstruktive Chirurgie, Linz
,
Lars-Peter Kamolz
1   LKH - Universitätsklinikum Graz/Klinische Abteilung für Plastische, Ästhetische & Rekonstruktive Chirurgie, Graz
,
Rupert Koller
6   Wilhelminenspital/Abteilung für Plastische und Wiederherstellungschirurgie, Wien
,
Christian Krasny
7   Orthopädisches Spital Speising/I. Orthopädische Abteilung, Wien
,
Martin Leixnering
8   Unfallkrankenhaus Lorenz Böhler/Unfallchirurgie Handchirurgie, Wien
,
Walpurga Lick-Schiffer
9   Landeskrankenhaus Stolzalpe, Stolzalpe
,
Matthias Rab
10   Klinikum Klagenfurt am Wörthersee /Abteilung für Plastische, Ästhetische und Rekonstruktive Chirurgie, Klagenfurt
,
Ingrid Schlenz
6   Wilhelminenspital/Abteilung für Plastische und Wiederherstellungschirurgie, Wien
,
Gottfried Wechselberger
11   Krankenhaus der Barmherzige Brüder Salzburg/Plastische, Rekonstruktive und Ästhetische Chirurgie, Salzburg
,
Gerlinde Weigel
12   Landesklinikum Mistelbach-Gänserndorf, Handzentrum, Mistelbach
,
Armin Zadra
13   Landeskrankenhaus Südsteiermark Standort Bad Radkersburg/Abteilung für Orthopädie, Bad Radkersburg
,
Robert Zimmermann
3   Univ.-Klinik für Plastische, Rekonstruktive und Ästhetische Chirurgie Innsbruck, Innsbruck
› Institutsangaben
Weitere Informationen

Publikationsverlauf

09/07/2017

04/25/2018

Publikationsdatum:
17. Oktober 2018 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Die Dupuytren’sche Kontraktur (DK) oder Morbus Dupuytren ist eine progressive fibroproliferative Erkrankung des palmoplantaren Bindegewebes, bei der es zu einer charakteristischen Knoten- und/oder Strangbildung aus Kollagen kommt. Bei fortschreitender Erkrankung führt die Strangverdickung zu einer Beugekontraktur des betroffenen Fingers, die in einer deutlichen Behinderung der Betroffenen münden kann, insbesondere bei beidseitigem Befall.

Die Erkrankung ist in Europa relativ verbreitet, wobei die Prävalenz in nordischen Ländern am höchsten ist. In Österreich geht man von rund 200 000 Betroffenen aus. Die Inzidenz steigt mit zunehmendem Alter, wobei Männer häufiger und früher erkranken als Frauen.

Die Ätiologie der DK ist nicht vollständig geklärt, scheint jedoch multifaktoriell zu sein, wobei eine genetische Prädisposition als gesichert gilt. Der natürliche Verlauf der Erkrankung kann zwischen relativ gutartig und massiver Progredienz und Rezidivhäufigkeit variieren. Zumeist findet sich ein schubweiser Verlauf.

Die DK ist nicht heilbar; die Behandlungsmethoden reichen von minimalinvasiven bis zu offenen chirurgischen Verfahren. Collagenase Clostridium histolyticum (CCH) ist eine nichtchirurgische, enzymatische Injektionsbehandlung für erwachsene Patienten (≥ 18 Jahre), die in Europa seit 2011 zur Behandlung der DK mit einem tastbaren Strang zugelassen ist. Klinische Studien und praktische Erfahrungen einzelner Zentren bestätigen die Wirksamkeit und Sicherheit der CCH-Behandlung von Beugekontrakturen.

Das vorliegende Konsensus Statement wurde unter der Ägide der Österreichischen Gesellschaft für Handchirurgie und der Mitwirkung der Österreichischen Gesellschaften für Unfallchirurgie, Orthopädie und orthopädische Chirurgie sowie für Plastische, Ästhetische und Rekonstruktive Chirurgie erstellt. Es beschreibt die verschiedenen chirurgischen Verfahren unter besonderer Berücksichtigung der Kollagenase-Behandlung und stellt eine Orientierungshilfe für deren Einsatz dar. Das Statement soll nicht nur den Stand des Wissens der DK-Behandlung abbilden, sondern auch als Richtschnur dienen und zu einem einheitlich hohen Qualitätsstandard der Kontraktur-Behandlung in chirurgischen Zentren und spezialisierten Arztpraxen in ganz Österreich beitragen.

Abstract

Dupuytren’s contracture (DC) or Dupuytren’s disease (DD) is a progressive fibro-proliferative disease of palmoplantar connective tissue, resulting in characteristic nodal and/or cord formation from collagen disposition. When the disease progresses, the thickening and shortening of the cords eventually leads the affected fingers to being pulled into flexion, which may be associated with marked disability, especially with bilateral disease. DD is relatively common in Europe, with the highest prevalence in Nordic countries. In Austria approx. 200 000 people are affected. The incidence increases with increasing age, with men being more often and earlier affected than women. The aetiology of DC is not completely clear, but it seems to be multifactorial; twin and familial studies confirm a genetic predisposition. The natural course of the disease can vary between relatively benign and massive progression and recurrence. In most cases, there is a fluctuating course. The DC is not curable; treatment methods range from minimally invasive to open surgical procedures. Collagenase Clostridium histolyticum (CCH) is a nonsurgical, enzymatic injection treatment for adult patients (≥ 18 years) with a palpable cord and has been approved in Europe since 2011. Clinical studies and practical experience of individual centres confirm the efficacy and safety of CCH treatment of DC. The present consensus statement was prepared under the auspices of the Austrian Society of Hand Surgery with the participation of the Austrian Society for Trauma Surgery, the Society of Orthopaedics and Orthopaedic Surgery as well as the Society for Plastic, Aesthetic and Reconstructive Surgery. On the basis of current literature and the experts’ experience, it describes the various surgical procedures, with particular reference to collagenase treatment and provides guidance for their use. The statement is intended not only to illustrate the state of the art of current treatment, but also to support the achievement of uniform high quality standards in the treatment of DC in surgical centres and specialised medical practices throughout Austria.

Schlüsselwörter

Handchirurgie - Dupuytren’sche Kontraktur - Kollagenase - Wirksamkeit - Sicherheit

Key words

Dupuytren’s contracture - collagenase - efficacy - safety

Fußnote

1 Konsensus Statement unter der Ägide der Österreichischen Gesellschaft für Handchirurgie unter Mitwirkung der Österreichischen Gesellschaft für Unfallchirurgie, Österreichischen Gesellschaft für Orthopädie und orthopädische Chirurgie sowie der Österreichischen Gesellschaft für Plastische, Ästhetische und Rekonstruktive Chirurgie


 

  • Literatur

  • 1 Pillukat T, Walle L, Stüber R. et al. Rezidiveingriffe beim Morbus Dupuytren 2017; 46: 342-352
    PubMedSuche in Google Scholar
  • 2 Lanting R, Van Den Heuvel ER, Westerink B. et al. Prevalence of Dupuytren disease in the Netherlands. Plast Reconstr Surg 2013; 132: 394-403
    CrossrefPubMedSuche in Google Scholar
  • 3 Lanting R, Broekstra DC, Werker PM. et al. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg 2014; 133: 593-603
    CrossrefPubMedSuche in Google Scholar
  • 4 Hindocha S, Mcgrouther DA, Bayat A. Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand (NY) 2009; 4: 256-269
    CrossrefPubMedSuche in Google Scholar
  • 5 Mikkelsen OA. Dupuytren’s disease--a study of the pattern of distribution and stage of contracture in the hand. Hand 1976; 8: 265-71
    CrossrefPubMedSuche in Google Scholar
  • 6 Wilbrand S, Ekbom A, Gerdin B. The sex ratio and rate of reoperation for Dupuytren’s contracture in men and women. J Hand Surg Br 1999; 24: 456-9
    PubMedSuche in Google Scholar
  • 7 Anthony SG, Lozano-Calderon SA, Simmons BP. et al. Gender ratio of Dupuytren’s disease in the modern U.S. population. Hand (N Y) 2008; 3: 87-90
    CrossrefPubMedSuche in Google Scholar
  • 8 Henry M. Dupuytren’s disease: current state of the art. HAND 2014; 9: 1-8
    CrossrefPubMedSuche in Google Scholar
  • 9 Ball C, Izadi D, Verjee LS. et al. Systematic review of non-surgical treatments for early Dupuytren’s disease. BMC Musculoskelet Disord 2016; 17: 345
    CrossrefPubMedSuche in Google Scholar
  • 10 Capstick R, Bragg T, Giele H. et al. Sibling recurrence risk in Dupuytren’s disease. J Hand Surg Eur Vol 2013; 38: 424-9
    CrossrefPubMedSuche in Google Scholar
  • 11 Larsen S, Krogsgaard DG, Aagaard Larsen L. et al. Genetic and environmental influences in Dupuytren’s disease: a study of 30,330 Danish twin pairs. J Hand Surg Eur Vol 2015; 40: 171-6
    CrossrefPubMedSuche in Google Scholar
  • 12 Dolmans GH, Werker PM, Hennies HC. et al. Dutch Dupuytren Study Group; German Dupuytren Study Group; Life Lines Cohort Study; BSSH-GODD Consortium. Wnt signaling and Dupuytren’s disease. N Engl J Med 2011; 365: 307-17
    CrossrefPubMedSuche in Google Scholar
  • 13 Becker K, Siegert S, Toliat MR. et al. German Dupuytren Study Group. Meta-Analysis of Genome-Wide Association Studies and Network Analysis-Based Integration with Gene Expression Data Identify New Suggestive Loci and Unravel a Wnt-Centric Network Associated with Dupuytren’s Disease. PLoS One 2016; 11: e0158101
    CrossrefPubMedSuche in Google Scholar
  • 14 van Beuge MM, Ten Dam EJ, Werker PM. et al. Wnt pathway in Dupuytren disease: connecting profibrotic signals. Transl Res 2015; 166: 762-771
    CrossrefPubMedSuche in Google Scholar
  • 15 Verjee LS, Verhoekx JS, Chan JK. et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A 2013; 110: E928-37
    CrossrefPubMedSuche in Google Scholar
  • 16 Dolmans GH, de Bock GH, Werker PM. Dupuytren diathesis and genetic risk. J Hand Surg Am 2012; 37: 2106-11
    CrossrefPubMedSuche in Google Scholar
  • 17 Abe Y, Rokkaku T, Ofuchi S. et al. An objective method to evaluate the risk of recurrence and extension of Dupuytren’s disease. J Hand Surg Br 2004; 29: 427-30
    CrossrefPubMedSuche in Google Scholar
  • 18 Hindocha S, Stanley JK, Watson S. et al. Dupuytren’s diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg 2006; 31A: 1626-1634
    PubMedSuche in Google Scholar
  • 19 Geoghegan JM, Forbes J, Clark DI. et al. Dupuytren’s disease risk factors. J Hand Surg Br 2004; 29: 423-426
    PubMedSuche in Google Scholar
  • 20 Lucas G, Brichet A, Roquelaure Y. et al. Dupuytren’s disease: personal factors and occupational exposure. Am J Ind Med 2008; 51: 9-15
    CrossrefPubMedSuche in Google Scholar
  • 21 Loos B, Puschkin V, Horch RE. 50 years experience with Dupuytren’s contracture in the Erlangen University Hospital--a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord 2007; 8: 60
    CrossrefPubMedSuche in Google Scholar
  • 22 Felici N, Marcoccio I, Giunta R. et al. Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence. Handchir Mikrochir Plast Chir 2014; 46: 350-354
    Thieme ConnectPubMedSuche in Google Scholar
  • 23 Luck JV. Dupuytren’s contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am 1959; 41-A: 635-664
    PubMedSuche in Google Scholar
  • 24 Millesi H. Dupuytren-Kontraktur. In: Berger A, Hierner R. (Hrsg.) Plastische Chirurgie. Band IV: Extremitäten. Springer; 2009: S83-111
    CrossrefSuche in Google Scholar
  • 25 von Campe A, Mende K, Omaren H. et al. Painful nodules and cords in Dupuytren disease. J Hand Surg Am 2012; 37: 1313-8
    CrossrefPubMedSuche in Google Scholar
  • 26 Iselin M. Les formes du maladie de Dupuytren. Concours Med 1955; 77: 4769-71
    PubMedSuche in Google Scholar
  • 27 Tubiana R, Michon J, Thomine JM. Scheme for the assessment of deformities in Dupuytren’s disease. Surg Clin North Am 1968; 48: 979-984
    CrossrefPubMedSuche in Google Scholar
  • 28 Rayan GM. Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 2007; 89: 189-98
    CrossrefPubMedSuche in Google Scholar
  • 29 Kadhum M, Smock E, Khan A. et al. Radiotherapy in Dupuytren’s disease: a systematic review of the evidence. J Hand Surg Eur Vol 2017; 42: 689-692
    CrossrefPubMedSuche in Google Scholar
  • 30 Betz N, Ott OJ, Adamietz B. et al. Radiotherapy in early-stage Dupuytren’s contracture. Long-term results after 13 years. Strahlenther Onkol 2010; 186: 82-90
    CrossrefPubMedSuche in Google Scholar
  • 31 Seegenschmiedt MH, Piefel K, Schneider T. Radiation therapy for hyperproliferative benign disease. In: Warwick D. (Ed.) Dupuytren’s Disease. FESSH Instructional Course 2015. Edizioni Medico-Scientifiche; 2015: 81-92
    Suche in Google Scholar
  • 32 Warwick D. (Ed.) Dupuytren’s Disease. FESSH Instructional Course 2015. Edizioni Medico-Scientifiche; 2015
    Suche in Google Scholar
  • 33 Brenner P, Rayan GM. (Hrsg.) Morbus Dupuytren. Ein chirurgisches Therapiekonzept. Springer; 2002
    Suche in Google Scholar
  • 34 Coert JH, Nerin JP, Meek MF. Results of partial fasciectomy for Dupuytren disease in 261 consecutive patients. Annals of Plastic Surgery 2006; 57: 13-7
    CrossrefPubMedSuche in Google Scholar
  • 35 Dias JJ, Braybrooke J. Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg Br 2006; 31: 514-21
    CrossrefPubMedSuche in Google Scholar
  • 36 Citron ND, Nunez V. Recurrence after surgery for Dupuytren’s disease: a randomized trial of two skin incisions. J Hand Surg Br 2005; 30: 563-6
    CrossrefPubMedSuche in Google Scholar
  • 37 Norotte G, Apoil A, Travers V. A ten years follow-up of the results of surgery for Dupuytren’s disease. A study of fifty-eight cases. Ann Chir Main 1988; 7: 277-81
    CrossrefPubMedSuche in Google Scholar
  • 38 Moermans JP. Segmental aponeurectomy in Dupuytren’s disease. J Hand Surg Br 1991; 16: 243-54
    CrossrefPubMedSuche in Google Scholar
  • 39 Moermans JP. Long-term results after segmental aponeurectomy for Dupuytren’s disease. J Hand Surg Br 1996; 21: 797-800
    CrossrefPubMedSuche in Google Scholar
  • 40 Clibbon JJ, Logan AM. Palmar segmental aponeurectomy for Dupuytren’s disease with metacarpophalangeal flexion contracture. J Hand Surg Br 2001; 26: 360-1
    CrossrefPubMedSuche in Google Scholar
  • 41 Brenner P. Die Dupuytren-Kontraktur an Ring- und Kleinfinger. Operat Orthop Traumatol 2002; 14: 150-71
    CrossrefPubMedSuche in Google Scholar
  • 42 Brenner P, Krause-Bergmann A, HaVan V. Die Dupuytren-Kontraktur in Norddeutschland. Epidemiologische Erfassungsstudie anhand von 500 Fällen Unfallchirurg 2001; 104: 30-311
    PubMedSuche in Google Scholar
  • 43 Hueston JT. Limited fasciectomy for Dupuytren’s contracture. Plast Reconstr Surg Transplant Bull 1961; 27: 569-85
    CrossrefPubMedSuche in Google Scholar
  • 44 Hueston JT. Recurrent Dupuytren’s contracture. Plast Reconstr Surg 1963; 31: 66-9
    CrossrefPubMedSuche in Google Scholar
  • 45 Denkler K. Surgical complications associated with fasciectomy for Dupuytren’s disease: a 20-year review of the English literature. Eplasty 2010; 10: e15
    PubMedSuche in Google Scholar
  • 46 Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren’s contracture surgery. J Hand Surg Am 2005; 30: 1021-5
    CrossrefPubMedSuche in Google Scholar
  • 47 De Seze S, Debeyre N. Traitement de la maladie de Dupuytren par l’hydrocrtisone locale associée aux manoeuvres de redressement (70 cas traits). Rev Rhum 1957; 24: 540-550
    PubMedSuche in Google Scholar
  • 48 Foucher G, Medina J, Navarro R. [Percutaneous needle aponeurotomy. Complications and results]. Chir Main 2001; 20: 206-11
    CrossrefPubMedSuche in Google Scholar
  • 49 Oppermann J, Unglaub F, Müler IP. et al. Perkutane Nadelaponeurotomie bei Dupuytren-Kontraktur. Orthopäde 2017; 46: 315-320
    CrossrefPubMedSuche in Google Scholar
  • 50 Meinel A, Assmus H, Reininger H-U. et al. Die perkutane Nadelfasziotomie bei der fortgeschrittenen Dupuytren’schen Fingerkontraktur. Obere Extremität 2008; 3: 187-192
    CrossrefPubMedSuche in Google Scholar
  • 51 van Rijssen AL, Werker PM. Percutaneous needle fasciotomy for recurrent Dupuytren disease. J Hand Surg Am 2012; 37 (09) 1820-3
    CrossrefPubMedSuche in Google Scholar
  • 52 Foucher G, Lallemand S, Pajardi G. Quoi de neuf dans le traitment de la maladie de Dupuytren?. Ann Chir Plast Esthet 1998; 43: 593-599
    PubMedSuche in Google Scholar
  • 53 van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren’s disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg 2012; 129: 469-77
    CrossrefPubMedSuche in Google Scholar
  • 54 Werker P, Reichert B. Percutaneous needle fasciotomy. In: Warwick D. (Ed.) Dupuytren’s Disease. FESSH Instructional Course 2015. Edizioni Medico-Scientifiche; 2015: 141-147
    Suche in Google Scholar
  • 55 Symes T, Stothard J. Two significant complications following percutaneous needle fasciotomy in a patient on anticoagulants. J Hand Surg Br 2006; 31: 606-7
    CrossrefPubMedSuche in Google Scholar
  • 56 Leclerq C. Complications du traitment médical de la maladie de Dupuytren. In: Simon L, Revel M, Rodineau J. (Eds) Main et Médicine Orthopedique. Paris: Masson; 1997: 152-158
    Suche in Google Scholar
  • 57 Rydevik B, Brown MD, Ehira T. et al. Effects of collagenase on nerve tissue. An experimental study on acute and long-term effects in rabbits. Spine 1985; 10: 562-566
    CrossrefPubMedSuche in Google Scholar
  • 58 Rydevik B, Ehira T, Linder L. et al. Microvascular response to locally injected collagenase. An experimental investigation in hamsters and rabbits. Scand J Plast Reconstr Surg Hand Surg 1989; 23: 17-21
    PubMedSuche in Google Scholar
  • 59 Auxilium. Briefing Document for Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Advanced Dupuytren’s Disease. Arthritis Advisory Committee Meeting: 16 September 2009. Im Internet verfügbar unter (Zugriff 30. April 2017): https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM182015.pdf
    PubMed
  • 60 Warwick D, Arandes-Renú JM, Pajardi G. et al. Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances. J Plast Surg Hand Surg 2016; 50: 251-61
    CrossrefPubMedSuche in Google Scholar
  • 61 Hurst LC, Badalamente MA, Hentz VR. et al CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009; 361: 968-79
    CrossrefPubMedSuche in Google Scholar
  • 62 Gilpin D, Coleman S, Hall S. et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 2010; 35: 2027-38
    CrossrefPubMedSuche in Google Scholar
  • 63 Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am 2007; 32: 767-74
    CrossrefPubMedSuche in Google Scholar
  • 64 Witthaut J, Jones G, Skrepnik N. et al. Efficacy and safety of collagenase clostridium histolyticum, a nonsurgical treatment for adults with Dupuytren’s contracture: short-term results from two open-label studies, in the US (JOINT I) and Australia and Europe (JOINT II). J Hand Surg Am 2013; 38: 2e11
    PubMedSuche in Google Scholar
  • 65 Bainbridge C, Gerber RA, Szczypa PP. et al. Efficacy of collagenase in patients, who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg 2012; 46: 177-83
    CrossrefPubMedSuche in Google Scholar
  • 66 Peimer CA, Blazar P, Coleman S. et al. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data. J Hand Surg Am 2013; 38: 12-22
    CrossrefPubMedSuche in Google Scholar
  • 67 Peimer CA, Blazar P, Coleman S. et al. Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data. J Hand Surg Am 2015; 40: 1597-605
    CrossrefPubMedSuche in Google Scholar
  • 68 McGrouther DA, Jenkins A, Brown S. et al. The efficacy and safety of collagenase clostridium histolyticum in the treatment of patients with moderate Dupuytren’s contracture. Curr Med Res Opin 2014; 30: 733-9
    CrossrefPubMedSuche in Google Scholar
  • 69 Binter A, Neuwirth M, Rab M. Behandlung der Dupuytren’schen Kontraktur mit Kollagenase – Ein-Jahres-Follow-up-Analyse anhand von 37 Patienten. Handchir Mikrochir Plast Chir 2014; 46: 355-60
    Thieme ConnectPubMedSuche in Google Scholar
  • 70 Nydick JA, Olliff BW, Garcia MJ. et al. A comparison of percutaneous needle fasciotomy and collagenase injection for dupuytren disease. J Hand Surg Am 2013; 38: 2377-80
    CrossrefPubMedSuche in Google Scholar
  • 71 Vollbach F, Walle L, Fansa H. Morbus Dupuytren - Patientenzufriedenheit und funktionelle Ergebnisse ein Jahr nach partieller Aponeurektomie und Injektion von Kollagenase. Handchir Mikrochir plast Chir 2013; 45: 258-264
    Thieme ConnectPubMedSuche in Google Scholar
  • 72 Tay TK, Tien H, Lim EY. Comparison between Collagenase Injection and Partial Fasciectomy in the Treatment of Dupuytren’s Contracture. Hand Surg 2015; 20: 386-90
    CrossrefPubMedSuche in Google Scholar
  • 73 Baur E-M, Zimmermann R, Muller V. et al. Minimally Invasive Treatment of Dupuytren: Collagenase Versus PNF. Hand Am Vol. 2016 11. (1_suppl): 82S [abstract) presented at the IFSSH & IFSHT Triennial Congress in Buenos Aires 2016
    PubMedSuche in Google Scholar
  • 74 Scherman P, Jenmalm P, Dahlin LB. One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren’s contracture: A two-centre prospective randomized clinical trial. J Hand Surg Eur Vol 2016; 41: 577-82
    CrossrefPubMedSuche in Google Scholar
  • 75 Strömberg J, Ibsen-Sörensen A, Fridén J. Comparison of Treatment Outcome After Collagenase and Needle Fasciotomy for Dupuytren Contracture: A Randomized, Single-Blinded, Clinical Trial With a 1-Year Follow-Up. J Hand Surg Am 2016; 41: 873-80
    CrossrefPubMedSuche in Google Scholar
  • 76 Toftgaard Skov S, Bisgaard T, Søndergaard P. et al. Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial. J Hand Surg Am 2017; 42: 321-328
    CrossrefPubMedSuche in Google Scholar
  • 77 Zhou C, Hovius SE, Slijper HP. et al. Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren’s Contracture: Outcomes from a Multicenter Propensity Score Matched Study. Plast Reconstr Surg 2015; 136: 87-97
    PubMedSuche in Google Scholar
  • 78 Povlsen B, Povlsen SD. What is the better treatment for single digit dupuytren’s contracture: surgical release or collagenase clostridium histolyticum (Xiapex) injection?. Hand Surg 2014; 19: 389-92
    CrossrefPubMedSuche in Google Scholar
  • 79 Peimer CA, Skodny P, Mackowiak JI. Collagenase clostridium histolyticum for dupuytren contracture: patterns of use and effectiveness in clinical practice. J Hand Surg Am 2013; 38: 2370-6
    CrossrefPubMedSuche in Google Scholar
  • 80 Haerle M, Witthaut J, Giunta R. et al. Treatment of Dupuytren’s contracture with collagenase clostridium histolyticum under clinical practice conditions: ReDUCTo study. GMS Ger Plast Reconstr Aesthet Surg 2015; 5: Doc06 (20150818)
    PubMedSuche in Google Scholar
  • 81 Pototschnig A, Volkmer E, Giunta RE. [Treatment of Dupuytren‘s disease with collagenase injections in Germany: efficacy and adverse effects in 110 treated joints]. Handchir Mikrochir Plast Chir 2017; 49: 154-161
    Thieme ConnectPubMedSuche in Google Scholar
  • 82 Arora R, Kaiser P, Kastenberger TJ. et al. Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren’s disease. Oper Orthop Traumatol 2016; 28: 30-7
    CrossrefPubMedSuche in Google Scholar
  • 83 Bear BJ, Peimer CA, Kaplan TD. et al. Treatment of Recurrent Dupuytren Contracture in Joints Previously Effectively Treated With Collagenase Clostridium histolyticum. J Hand Surg Am 2017; 42: 391.e1-391.e8
    CrossrefPubMedSuche in Google Scholar
  • 84 Peimer CA, Wilbrand S, Gerber RA. et al. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol 2015; 40: 141-9
    CrossrefPubMedSuche in Google Scholar
  • 85 Peimer CA, McGoldrick CA, Fiore GJ. Nonsurgical treatment of Dupuytren’s contracture: 1-year US post-marketing safety data for collagenase clostridium histolyticum. Hand (N Y) 2012; 7: 143-6
    CrossrefPubMedSuche in Google Scholar
  • 86 Arabyat RM, Raisch DW, McKoy JM. et al. Fluoroquinolone-as- sociated tendon-rupture: a summary of reports in the Food and Drug Administration’s adverse event reporting system. Expert Opin Drug Saf 2015; 14: 1653-60
    CrossrefPubMedSuche in Google Scholar
  • 87 Golub LM, Lee HM, Ryan ME. et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26
    CrossrefPubMedSuche in Google Scholar
  • 88 [EMA, 2011]. Europeam Medicies Ageny. Assessment report Xiapex. Common name: Collagenase clostridium histolyticum Procedure No. EMEA/H/C/2048. Im Internet abrufbar unter: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002048/WC500103376.pdf
    PubMed
  • 89 Xiapex® Trainings-Handbuch für die Injektion. Sobi. 2016
    PubMedSuche in Google Scholar
  • 90 Mehta S, Belcher HJ. A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren’s contracture of the hand. J Plast Reconstr Aesthet Surg 2014; 67: 368-72
    CrossrefPubMedSuche in Google Scholar
  • 91 Neuwirth M, Binter A, Pipam W. et al. Kosteneffektivität der Behandlung von Patienten mit Dupuytren-Kontraktur mit mikrobieller Collagenase Clostridium histolyticum (Xiapex®) im Vergleich zur partiellen Fasziektomie in Östereich. Handchir Mikrochir Plast Chir 2016; 48: 233-8
    Thieme ConnectPubMedSuche in Google Scholar
  • 92 Sanjuan Cerveró R, Franco Ferrando N, Poquet Jornet J. Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord 2013; 14: 293
    CrossrefPubMedSuche in Google Scholar
  • 93 Chen NC, Shauver MJ, Chung KC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg Am 2011; 36: 1826-1834
    CrossrefPubMedSuche in Google Scholar
  • 94 Meals RA, Hentz VR. Technical tips for collagenase injection treatment for Dupuytren contracture. J Hand Surg Am 2014; 39 (06) 1195-200.e2
    CrossrefPubMedSuche in Google Scholar
  • 95 Degreef I. Collagenase Treatment in Dupuytren Contractures: A Review of the Current State Versus Future Needs. Rheumatol Ther 2016; 3 (01) 43-51
    CrossrefPubMedSuche in Google Scholar